1
|
Gallardo-Macias R, Russo R, Sherwood M, Jaskowski M, Nasser W, Sharma P, Tuckman M, Singleton E, Ho HP, Park S, Patel JS, George A, Perlin D, Zimmerman MD, Connell N, Freundlich JS. Small Molecule Benzothiophene with In Vivo Efficacy in a Mouse Model of Drug-Resistant Enterococcus faecium Infection. J Med Chem 2024; 67:1384-1392. [PMID: 38225186 DOI: 10.1021/acs.jmedchem.3c01846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2024]
Abstract
Hospital-acquired infections, caused by ESKAPE bacteria, are a challenging global public health concern, in part due to the emergence of drug-resistant strains. While profiling a diverse set of compounds for in vitro activity versus this class of bacteria, we noted that the benzothiophene JSF-2827 exhibited promising antibacterial activity against Enterococcus faecium. A hit evolution campaign ensued, involving the design, synthesis, and biological assay of analogues designed to address early issues such as a short mouse liver microsome half-life and a modest mouse pharmacokinetic profile. Among these derivatives, JSF-3269 was found to exhibit an enhanced profile and in vivo efficacy in an immunocompetent mouse model of acute, drug-resistant E. faecium infection. The findings suggest a rationale for the further evolution of this promising series to afford a novel therapeutic strategy to treat drug-resistant E. faecium infection.
Collapse
Affiliation(s)
- Ricardo Gallardo-Macias
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Riccardo Russo
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University─New Jersey Medical School, Newark 07103, New Jersey, United States
| | - Matthew Sherwood
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Mark Jaskowski
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Wissam Nasser
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Pankaj Sharma
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Margareta Tuckman
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University─New Jersey Medical School, Newark 07103, New Jersey, United States
| | - Eric Singleton
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University─New Jersey Medical School, Newark 07103, New Jersey, United States
| | - Hsin Pin Ho
- Public Health Research Institute, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Steven Park
- Public Health Research Institute, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Jimmy S Patel
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Amir George
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - David Perlin
- Public Health Research Institute, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Matthew D Zimmerman
- Public Health Research Institute, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
| | - Nancy Connell
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University─New Jersey Medical School, Newark 07103, New Jersey, United States
| | - Joel S Freundlich
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University─New Jersey Medical School, Newark, New Jersey 07103, United States
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University─New Jersey Medical School, Newark 07103, New Jersey, United States
| |
Collapse
|
2
|
Gallardo-Macias R, Kumar P, Jaskowski M, Richmann T, Shrestha R, Russo R, Singleton E, Zimmerman MD, Ho HP, Dartois V, Connell N, Alland D, Freundlich JS. Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent. Bioorg Med Chem Lett 2018; 29:601-606. [PMID: 30600207 DOI: 10.1016/j.bmcl.2018.12.053] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Revised: 12/20/2018] [Accepted: 12/22/2018] [Indexed: 12/17/2022]
Abstract
The optimization campaign for a nitrofuran antitubercular hit (N-benzyl-5-nitrofuran-2-carboxamide; JSF-3449) led to the design, synthesis, and biological profiling of a family of analogs. These compounds exhibited potent in vitro antitubercular activity (MIC = 0.019-0.20 μM) against the Mycobacterium tuberculosis H37Rv strain and low in vitro cytotoxicity (CC50 = 40->120 μM) towards Vero cells. Significant improvements in mouse liver microsomal stability and mouse pharmacokinetic profile were realized by introduction of an α, α-dimethylbenzyl moiety. Among these compounds, JSF-4088 is highlighted due to its in vitro antitubercular potency (MIC = 0.019 μM) and Vero cell cytotoxicity (CC50 > 120 μM). The findings suggest a rationale for the continued evolution of this promising series of antitubercular small molecules.
Collapse
Affiliation(s)
- Ricardo Gallardo-Macias
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Pradeep Kumar
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Mark Jaskowski
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Todd Richmann
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Riju Shrestha
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Riccardo Russo
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Eric Singleton
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Matthew D Zimmerman
- Public Health Research Institute, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Hsin Pin Ho
- Public Health Research Institute, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Véronique Dartois
- Public Health Research Institute, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Nancy Connell
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - David Alland
- Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA
| | - Joel S Freundlich
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University - New Jersey Medical School, Newark, NJ, USA; Division of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University - New Jersey Medical School, Newark, NJ, USA.
| |
Collapse
|
3
|
Chu J, Vila-Farres X, Inoyama D, Gallardo-Macias R, Jaskowski M, Satish S, Freundlich JS, Brady SF. Human Microbiome Inspired Antibiotics with Improved β-Lactam Synergy against MDR Staphylococcus aureus. ACS Infect Dis 2018; 4:33-38. [PMID: 28845973 DOI: 10.1021/acsinfecdis.7b00056] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The flippase MurJ is responsible for transporting the cell wall intermediate lipid II from the cytoplasm to the outside of the cell. While essential for the survival of bacteria, it remains an underexploited target for antibacterial therapy. The humimycin antibiotics are lipid II flippase (MurJ) inhibitors that were synthesized on the basis of bioinformatic predictions derived from secondary metabolite gene clusters found in the human microbiome. Here, we describe an SAR campaign around humimycin A that produced humimycin 17S. Compared to humimycin A, 17S is a more potent β-lactam potentiator, has a broader spectrum of activity, which now includes both methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococcus faecalis (VRE), and did not lead to any detectable resistance when used in combination with a β-lactam. Combinations of β-lactam and humimycin 17S provide a potentially useful long-term MRSA regimen.
Collapse
Affiliation(s)
- John Chu
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States
| | - Xavier Vila-Farres
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States
| | - Daigo Inoyama
- Department
of Pharmacology, Physiology, and Neuroscience, Rutgers University−New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, United States
| | - Ricardo Gallardo-Macias
- Department
of Pharmacology, Physiology, and Neuroscience, Rutgers University−New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, United States
| | - Mark Jaskowski
- Department
of Pharmacology, Physiology, and Neuroscience, Rutgers University−New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, United States
| | - Shruthi Satish
- Department
of Pharmacology, Physiology, and Neuroscience, Rutgers University−New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, United States
| | - Joel S. Freundlich
- Department
of Pharmacology, Physiology, and Neuroscience, Rutgers University−New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, United States
| | - Sean F. Brady
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States
| |
Collapse
|
4
|
Chu J, Vila-Farres X, Inoyama D, Ternei M, Cohen LJ, Gordon EA, Reddy BVB, Charlop-Powers Z, Zebroski HA, Gallardo-Macias R, Jaskowski M, Satish S, Park S, Perlin DS, Freundlich JS, Brady SF. Discovery of MRSA active antibiotics using primary sequence from the human microbiome. Nat Chem Biol 2016; 12:1004-1006. [PMID: 27748750 PMCID: PMC5117632 DOI: 10.1038/nchembio.2207] [Citation(s) in RCA: 109] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 08/11/2016] [Indexed: 01/21/2023]
Abstract
Here we present a natural product discovery approach, whereby structures are bioinformatically predicted from primary sequence and produced by chemical synthesis (synthetic-bioinformatic natural products, syn-BNPs), circumventing the need for bacterial culture and gene expression. When we applied the approach to nonribosomal peptide synthetase gene clusters from human-associated bacteria, we identified the humimycins. These antibiotics inhibit lipid II flippase and potentiate β-lactam activity against methicillin-resistant Staphylococcus aureus in mice, potentially providing a new treatment regimen.
Collapse
Affiliation(s)
- John Chu
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Xavier Vila-Farres
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Daigo Inoyama
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - Melinda Ternei
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Louis J. Cohen
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Emma A. Gordon
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Boojala Vijay B. Reddy
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Zachary Charlop-Powers
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| | - Henry A. Zebroski
- Proteomics Resource Center, The Rockefeller University, New York, New York, USA
| | - Ricardo Gallardo-Macias
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - Mark Jaskowski
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - Shruthi Satish
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - Steven Park
- Public Health Research Institute, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - David S. Perlin
- Public Health Research Institute, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - Joel S. Freundlich
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers University – New Jersey Medical School, Newark, New Jersey, USA
| | - Sean F. Brady
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, New York, USA
| |
Collapse
|
5
|
|